As described in my first article, the noninvasive prenatal testing ("NIPT") market is evolving at a pace that has rarely been seen in healthcare. This nascent market provides a compelling opportunity for investors able to see it through a fog of uncertainty. Sequenom (SQNM) has maintained market leadership, since their launch of MaterniT21 in October 2011. The investment challenge: decipher the financial reporting in order to recognize the value proposition.
Supplement the financials with performance metrics. The objectives of financial reporting include providing:
· Valuable information to existing and prospective investors, employees, and creditors.
· Content to determine the economic resources and obligations of an enterprise.
· Reports to assess the amounts, timing and uncertainties of prospective...
Only subscribers can access this article, which is part of the PRO research library covering 3,613 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: